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Abstract
Background: Glycosylated haemoglobin (HbA1c) and random blood glucose are markers of  chronic and acute hyperglycaemia 
respectively.
Objective: We compared HbA1c levels in ketoacidosis (DKA) occurring in known and newly diagnosed diabetes.
Methods: Retrospective review of  medical records for 83 DKA admissions in 2008 and 2009 with results for HbA1c at 
presentation
Results: There were 52 and 31 DKA admissions in known and newly diagnosed diabetes patients respectively. Fifty of  the 
83 DKA admissions were in females. The mean age (per admissions) and HbA1c of  all admissions are 43.4 ± 20.3 years 
(n=83) and 12.7 ± 3.4 % (n=83) respectively. Mean HbA1c in known Type 1, known Type 2 and newly diagnosed diabetes 
patients were similarly very high: 12.4 ± 3.3 %, 12.5 ± 3.3 %, 13.1 ± 3.7 %; P = 0.6828. The HbA1c levels in newly diagnosed 
diabetes patients less than 30 years (likely Type 1 diabetes) and ≥ 30 years (likely Type 2 diabetes) were similar. There was a 
tendency to significantly positive correlation between blood glucose and HbA1c in new diabetes patients.
Conclusions: In our setting, DKA is associated with markedly elevated HbA1c levels in known type 1, known type 2 and 
new onset diabetes. 
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Introduction
Glycosylated haemoglobin (HbA1c) is formed by the 
non-enzymatic glycation of  haemoglobin and typically 
reflects the average blood glucose level during the life 
span of  the red blood cell which is about 2-3 months 
[1]. It is currently the gold standard for assessing 
long term glycaemic control in diabetes mellitus [2] 
as it demonstrates good association with the chronic 
microvascular complications of  diabetes such as 
retinopathy, nephropathy and neuropathy [3]. 
Recently HbA1c has been included as a criterion for 
the diagnosis of  diabetes mellitus [4]. The HbA1c level 
is however, of  limited use in the setting of  certain 
haemoglobinopathies, haemolytic states [5, 6]. Random 
blood glucose however, is a reflection of  acute blood 
glucose level.
Diabetic ketoacodosis (DKA), a life threatening acute 
metabolic complication of  diabetes, may occur in 
people previously known with diabetes or present as the 
first manifestation of  diabetes [7]. Diabetic ketoacidosis 
as the first manifestation of  diabetes is most often 
associated with Type 1 diabetes due to the rapid and 
marked beta cells destruction with resultant absolute 
insulinopenia. The presence of  ketoacidosis at diagnosis 
of  Type 1 diabetes has been shown to be a marker of  
depleted beta cell reserve and poor metabolic state [8]. 
Type 2 diabetes is however, characterized by a chronic 
asymptomatic pre-clinical phase which progresses 
through a period of  insulin independence to insulin 
dependence. Diabetic ketoacidosis which depicts a state 
of  severe insulin deficiency is increasingly recognized as 
the initial manifestation of  Type 2 diabetes [9].   
The expectation is that of  a lower HbA1c in Type 1 
diabetes patients with DKA as the first manifestation of  
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diabetes when compared with Type 2 diabetes patients 
with DKA as the first manifestation of  diabetes. This 
is because Type 2 diabetes is characterized by a longer 
period of  asymptomatic hyperglycaemia than Type 1 
diabetes. We assessed and compared HbA1c (marker 
of  chronic hyperglycaemia) and random plasma glucose 
levels (marker of  acute hyperglycaemia) at presentation 
with DKA in patients with Known diabetes (Types 1 
and 2) and newly diagnosed diabetes. 
Materials and methods
Subjects: These were 83 admissions for DKA during 
the period 2008 and 2009 for which HbA1c results were 
available. Repeat admissions for DKA in patients that 
were already known to have diabetes before the year 
2008 were treated as separate admissions. No patient 
who was admitted during the period of  2008 and 2009 
with DKA as the initial manifestation of  diabetes 
represented to us with DKA during the 2 year period. 
Study design: Retrospective review of  medical records 
over the 2-year period of  2008 and 2009. Known Types 1 
and 2 diabetes were as categorized in the case records. 
Ethical approval: This was obtained from the Ethics 
committee, Faculty of  Health Sciences, Walter Sisulu 
University, Eastern Cape Province of  South Africa. 
Glycosylated haemoglobin assay: This was done 
by the National Health Laboratory Services (NHLS), 
Mthatha using Roche/Hitachi COBAS 6000 analyzer 
(Cobas c 501 module) with A1C-2 diagnostic system 
supplied by Roche (Roche Diagnostics GmbH, 
Mannheim, Germany). The assay was a turbidimetric 
inhibition immunoassay.
Plasma glucose assay: This was determined by an 
enzymatic reference method using hexokinase on 
the Roche/Hitachi (Cobas c 501 module), (Roche 
Diagnostics GmbH, Mannheim, Germany).
Statistical analysis: Qualitative data were expressed as 
frequency and proportions (%). Continuous data were 
reported as mean ± SD. In univariate analysis, the means 
of  the three study groups (Known Type 1, Known Type 
2, Newly diagnosed diabetes) were compared using one-
way Anova with Bonferroni Post-Hoc test. Chi-Square 
test was used to compare proportions. The Pearson 
simple correlation coefficient r and determination 
coefficient R2 from the line regression equation served 
to examine the association between blood glucose 
and HbA1c. Statistical package was SPSS (version 17, 
Chicago, Illinois). P ≤ 0.05 defined statistical significance 
between groups.
Results
There were 83 admissions comprising 31 that presented 
with the index DKA as the first manifestation of  
diabetes and 52 in patients already known with diabetes. 
Known Types 1 and 2 diabetes accounted for 20 and 
32 admissions respectively in known diabetic patients. 
Females were 60.2 % (n=50/83) of  all admissions. The 
mean age per admissions was 43.4 ± 20.3 years (n=83). 
Mean blood glucose and HbA1c levels were 33.5 ± 14.9 
mmol/L (n=83) and 12.7 ± 3.4 % (n=83) respectively. 
The proportions of  admissions in various HbA1c 
categories were 1.2 % (n=1/83) for HbA1c < 7 %, 20.5 
% (n=17/83) for HbA1c of  7-9.9 %, 55.4 % (n=46/83) 
for HbA1c of  10-15 % and 22.9 % (n=19/83) for 
HbA1c > 15 %.





New DM P value
Female (%) 70 (14/20) 56.3 (18/32) 58.1(18/31) 0.59
Age < 30 years (%) 85 (17/20) 3.1 (1/32) 35.5 (11/31) <0.01
Hyperosmolar (%) 5 (1/20) 15.6 (5/32) 32.3 (10/31) 0.04
Blood glucose > 33.3 
mmol/L (%)
40 (8/20) 28.1 (9/32)  41.9 (13/31)  0.48
Serum urea > 7 mmol/L 
(%)
70 (14/20) 18.8 (6/32) 41.9 (13/31) <0.01
Haemoglobin < 10 g/L 
(%)
15 (3/20) 28.1 (7/31) 10 (3/30) 0.40
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Table 1 shows that patients with known Type 1 in 
contrast to known Type 2 diabetes were predominantly 
below 30 years. Hyperosmolality (calculated effective 
serum osmolality > 320 mosm/Kg) was more common 
in newly diagnosed diabetes than known Types 1 and 2 
diabetes patients. The proportion of  admissions with 
elevated serum urea (serum urea > 7 mmol/L) was 
higher with known Type 1 than other groups. 





New DM P value
Mean HbA1c (%) 12.4+3.3 12.5+3.3 13.1+3.7 0.68

















Table 2 shows comparably high mean HbA1c levels 
irrespective of  diabetes type. The majority of  admissions 
had HbA1c in the range of  10-15 % in all diabetes 
types. The only admission with an HbA1c of  less 
than 7 % which is the American Diabetes Association 
(ADA) criterion for optimal glycaemic control [10] was 
a known Type 1 diabetes patient with infection as the 
precipitating cause for DKA.
Table 3: Proportions of  admissions categorized by HbA1c and precipitating factor



























Table 3 shows high HbA1c levels irrespective of  
the precipitating factor for DKA. The majority of  
admissions associated with non compliance as the 
precipitating factor had HbA1c levels of  ≥ 10 %.
Table 4: Proportions of  admissions in newly diagnosed 
diabetes categorized by HbA1c and age
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Age < 30 years
(Likely Type 1 DM)
Age ≥ 30 years














Table 4 shows the proportions of  admissions in newly 
diagnosed diabetes categorized by HbA1c and age. The 
11 newly diagnosed diabetes patients who were less than 
30 years of  age and therefore, likely to be predominantly 
Type 1 diabetes all had HbA1c levels ≥ 10 %. These 11 
patients who were below 30 years of  age had similar 
HbA1c profiles as patients ≥ 30 years who are likely to 
be mainly Type 2 diabetics.
Figures 1 to 3 show linear regression lines interposed on 
scatter plots of  blood glucose and HbA1c for, known 
Type 2 diabetes (Figure 1), known Type 1 diabetes 
(Figure 2) and newly diagnosed diabetes patients 
(Figure 3). There was a tendency to significant positive 
correlation between blood glucose and Hba1c in newly 
diagnosed diabetes (n=31), r=0.346; P=0.056. There 
was non-significant correlations between blood glucose 
and HbA1c in Type 2 diabetes (n=32), r=0.156; P=0.394 
and Type 1 diabetes (n=20), r= -0.076; P=0.076.
Figure 1. Linear regression equation of  blood glucose and HbA1c in Type 2 diabetes patients.
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Figure 2. Linear regression equation of  blood glucose and HbA1c in Type 1 diabetes patients.
 
Figure 3. Linear regression equation of  blood glucose and HbA1c in newly diagnosed diabetes patients.
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Discussion
The major finding of  this retrospective review is that 
almost all admissions for DKA were associated with 
markedly elevated HbA1c levels at presentation. This 
was regardless of  whether patients were already known 
with Types 1 and 2 diabetes or only just diagnosed with 
diabetes at presentation with the index DKA. Although 
DKA is regarded as an acute metabolic complication of  
diabetes, the findings of  very high HbA1c levels in this 
study, suggests that in our setting, DKA occurs in the 
background of  chronic hyperglycaemia in both known 
and newly diagnosed diabetes. We have therefore since 
stopped requesting for HbA1c at presentation with 
DKA. We rather perform HbA1c during clinic visit 
at 3 months following discharge from a DKA related 
admission.
The tendency (P=0.06) to significant positive correlation 
between blood glucose and HbA1c levels in newly 
diagnosed diabetes is likely a reflection of  concurrent 
increase in both blood glucose and HbA1c with no 
interference from glucose lowering therapy. The negative 
correlation that was seen with Type 1 diabetes, though 
not significant may be partly explained by sudden onset 
severe hyperglycaemia due to marked insulinopenia 
such that the blood glucose levels become discordantly 
higher than the HbA1c levels. The rather gradual slope 
seen with Type 2 diabetes in contrast to the steep slope 
of  newly diagnosed diabetes group is possibly an effect 
of  glucose lowering therapy.
Our findings are similar to that of  another study [11] 
which reported HbA1c levels of  10.4% - 16.9% in 
patients with DKA as the first manifestation of  diabetes. 
One might have expected the newly diagnosed diabetes 
patients less than 30 years to have lower HbA1c levels 
than patients who are 30 years of  age and above. This 
is because the majority of  newly diagnosed diabetes 
patients who are less than 30 years are likely to have 
Type 1 diabetes [12] which is expected to have an acute 
pathogenesis. A study [12] of  60 persons with diabetes 
all less than 30 years of  age who were classified as Types 
1A, 1B and Type 2 based on beta cell autoimmunity and 
insulin reserve showed that the proportions of  Types 
1A, 1B and 2 were 55%, 30% and 15% respectively. 
The high HbA1c levels in our newly diagnosed diabetes 
patients below 30 years indicates that even where DKA is 
the first manifestation of  Type 1 diabetes, there has been 
hyperglycaemia of  sufficiently long duration of  time to 
result in markedly elevated HbA1c levels. The Diabetes 
Prevention Trial-Type 1 (DPT) found a relatively 
normal mean HbA1c of  6.41±1.5% at diagnosis, in 
asymptomatic Type 1 diabetes [13], suggesting that 
DKA may be a late manifestation of  Type 1 diabetes. 
Although screening for Type 1 diabetes is currently not 
the norm, early presentation and treatment is desirable 
before glycaemia deteriorates to the degree where DKA 
supervenes. 
The study showed similar HbA1c profiles irrespective 
of  the precipitating factor (Table 3). The majority of  
admissions that were associated with non-compliance 
to medications as the precipitating factor had markedly 
elevated HbA1c levels indicating that these are persons 
with long standing poor glycaemic control which 
probably rendered them easily susceptible to developing 
ketoacidosis. 
The association between elevated HbA1c and DKA in 
new onset and known diabetic patients may be related 
to chronic hyperglycaemia as this has been hypothesized 
to cause metabolic decompensation by impairing the 
functions of  the beta cell reserve and insulin receptor 
via the mechanism of  glucose toxicity [14]. Perhaps, 
improving long term glycaemic control in the known 
diabetic patient may reduce presentations for DKA. 
The limitations of  this study include categorizing 
patients with DKA in new onset diabetes with the age 
cut off  of  30 years. There was no data on markers of  
beta cell autoimmunity and insulin reserve which will 
have allowed for better classification as Type 1 or 2 
diabetes.  However, a recent study [15] in our centre 
showed the majority of  patients below 30 years of  age 
with DKA at diagnosis of  diabetes to be Type 1 based 
on positive anti-glutamic acid decarboxylase status and 
low plasma C-peptide response to intravenous injection 
of  glucagon. The presence of  Type 2 diabetes cannot 
be excluded particularly in young persons with HbA1c 
above 10% considering the increasing prevalence of  
Type 2 diabetes in the young [16].
Conclusion
Diabetic ketoacidosis in our environment is associated 
with very high HbA1c levels irrespective of  the Type 
and duration of  diabetes or precipitating factor for 
DKA. The clinical care implications are that stable 
patients with very high HbA1c levels should have 
glycaemia aggressively managed to avert the occurrence 
of  DKA. There is no value in measuring HbA1c levels 
at presentation with DKA.
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